


Amendments to the Claims

1- 8 (Canceled)

9. (Currently amended) A compound of structural formula I:



or a pharmaceutically acceptable salt thereof, wherein

each n is independently 0, 1, or 2;

R<sup>1</sup> is methyl;

R<sup>2</sup> is aryl or heteroaryl, or heteroarylmethyl, wherein aryl and heteroaryl are unsubstituted or substituted with one to four R<sup>6</sup> substituents;

R<sup>3</sup> is hydrogen, chlorine, or methyl;


R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a 5- to 7-membered ring saturated heterocycle optionally containing an additional heteroatom selected from O, S, and NC(0-4 alkyl) wherein said heterocycle optionally fused with a benzene ring and wherein said heterocycle or optionally benzo-fused heterocycle is unsubstituted or substituted with one to three substituents independently selected from halogen, C<sub>1-4</sub> alkyl, trifluoromethyl, and (CH<sub>2</sub>)<sub>n</sub>aryl wherein aryl is unsubstituted or substituted with one to three substituents independently selected from halogen and C<sub>1-4</sub> alkyl; and

each R<sup>6</sup> is independently selected from the group consisting of: amino, C<sub>1-4</sub> alkylamino, di(C<sub>1-4</sub> alkyl)amino, halogen, cyano, C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfonyl, trifluoromethyl, trifluoromethoxy, aryl, and heteroaryl;

wherein aryl and heteroaryl are unsubstituted or substituted with one to three substituents independently selected from cyano, halogen, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl, trifluoromethyl, and trifluoromethoxy. The compound of Claim 8 wherein R<sup>1</sup> is methyl; R<sup>2</sup> is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R<sup>6</sup> substituents; and R<sup>3</sup> is hydrogen, methyl or chlorine.

10- 11 (Canceled)

12. (Currently amended) A compound of structural formula I:



or a pharmaceutically acceptable salt thereof, wherein

each n is independently 0, 1, or 2;

R<sup>1</sup> is methyl;

R<sup>2</sup> is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to four R<sup>6</sup> substituents;

R<sup>3</sup> is hydrogen, chlorine or methyl;

R<sup>4</sup> is hydrogen;











R<sup>5</sup> is adamantyl or bicycloalkyl, unsubstituted or substituted with one to three substituents independently selected from methyl, hydroxy, and halogen; and

each R<sup>6</sup> is independently selected from the group consisting of: amino, C<sub>1-4</sub> alkylamino, di(C<sub>1-4</sub> alkyl)amino, halogen, cyano, C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfonyl, trifluoromethyl, trifluoromethoxy, aryl, and heteroaryl;


wherein aryl and heteroaryl are unsubstituted or substituted with one to three substituents independently selected from cyano, halogen, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl, trifluoromethyl, and trifluoromethoxy.

The compound of Claim 1 wherein R<sup>1</sup> is methyl; R<sup>2</sup> is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R<sup>6</sup> substituents; R<sup>3</sup> is hydrogen, methyl or chlorine; R<sup>4</sup> is hydrogen; and R<sup>5</sup> is adamantyl or bicyclo[2.2.1]heptyl, unsubstituted or substituted with one to three substituents independently selected from methyl, hydroxy, and halogen.

13. (Currently amended) A compound in accordance with claim 4  
12 selected from the group consisting of:


	
	
	
	
	

and
















or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

14. (Currently amended) A compound ~~in accordance with claim~~  
~~1-according to structural formula Ia~~, selected from the following table:



Ex.	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
3	Me	2-F-phenyl	Cl	
4	Me	2-Br-phenyl	Me	
5	Me	2-Cl-phenyl	Me	
6	Me	2-Cl-phenyl	Cl	
7	Me	2-Cl-phenyl	Cl	
8	Me	2-Cl-phenyl	H	
9	Me	2-CF <sub>3</sub> -phenyl	Me	
10	Me	3-OMe-phenyl	Me	

11	Me	2,4-di-F-phenyl	Me	
12	Me		Me	
13	Me	2-Me-phenyl	Me	
14	Me		Me	
15	Me	2-F-phenyl	Cl	
16	Me	4-OCF <sub>3</sub> -phenyl	Cl	
17	Me	2-Cl-phenyl	Cl	
18	CH(CH <sub>3</sub> ) <sub>2</sub>	4-Cl-phenyl	Me	
19	CH <sub>2</sub> CF <sub>3</sub>	4-Cl-phenyl	Me	
20	H	4-Cl-phenyl	Cl	
21	Me	Benzyl	Me	

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

15. (Canceled)

16. (Withdrawn) A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient an effective amount of a compound in accordance with Claim 1.

17. (Withdrawn) A method of treating non-insulin dependent diabetes mellitus in a mammalian patient in need of such treatment comprising administering to the patient an anti-diabetic effective amount of a compound in accordance with Claim 1.

18. (Withdrawn) A method of treating obesity in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat obesity.

19. (Withdrawn) A method of treating Syndrome X in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat Syndrome X.

20. (Withdrawn) A method of treating a lipid disorder selected from the group consisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat said lipid disorder.

21. (Withdrawn) A method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount effective to treat atherosclerosis.